Gil Ben-Menachem
Profile
Gil Ben-Menachem served as Chief Executive Officer at OphthaliX, Inc. in 2013.
Prior to that, he was Director of Business Development at Teva Pharmaceutical Industries Ltd., Head of Innovative Products at Dexcel Pharma Technologies Ltd., and Vice President of Business Development at Purple Biotech Ltd.
Ben-Menachem holds a Master's in Business Administration from the University of Maryland and undergraduate, graduate, and doctorate degrees from The Hebrew University of Jerusalem.
Former positions of Gil Ben-Menachem
Companies | Position | End |
---|---|---|
OphthaliX, Inc.
OphthaliX, Inc. Pharmaceuticals: MajorHealth Technology OphthaliX, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of therapeutic products for ophthalmic disorders. Its portfolio includes CF101 oral drug that intends to treat glaucoma and uveitis. The company was founded by Ilan Cohn on December 10, 1999 and is headquartered in Petach Tikva, Israel. | President | 2013-02-24 |
TEVA PHARMACEUTICAL INDUSTRIES LIMITED | Corporate Officer/Principal | - |
Dexcel Pharma Technologies Ltd.
Dexcel Pharma Technologies Ltd. Pharmaceuticals: MajorHealth Technology Dexcel Pharma Technologies Ltd. develops, manufactures and markets branded and generic pharmaceuticals. Its core products include Deximune, PerioChip, and Omeprazole delayed released tablet. The company was founded by Dan Oren in 1968 and is headquartered in Or Akiva, Israel. | Corporate Officer/Principal | - |
PURPLE BIOTECH LTD | Director/Board Member | - |
Training of Gil Ben-Menachem
University of Maryland | Masters Business Admin |
The Hebrew University of Jerusalem | Doctorate Degree |
Experiences
Positions held
Linked companies
Listed companies | 2 |
---|---|
TEVA PHARMACEUTICAL INDUSTRIES LIMITED | Health Technology |
PURPLE BIOTECH LTD | Health Technology |
Private companies | 2 |
---|---|
OphthaliX, Inc.
OphthaliX, Inc. Pharmaceuticals: MajorHealth Technology OphthaliX, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of therapeutic products for ophthalmic disorders. Its portfolio includes CF101 oral drug that intends to treat glaucoma and uveitis. The company was founded by Ilan Cohn on December 10, 1999 and is headquartered in Petach Tikva, Israel. | Health Technology |
Dexcel Pharma Technologies Ltd.
Dexcel Pharma Technologies Ltd. Pharmaceuticals: MajorHealth Technology Dexcel Pharma Technologies Ltd. develops, manufactures and markets branded and generic pharmaceuticals. Its core products include Deximune, PerioChip, and Omeprazole delayed released tablet. The company was founded by Dan Oren in 1968 and is headquartered in Or Akiva, Israel. | Health Technology |
- Stock Market
- Insiders
- Gil Ben-Menachem